Semaglutide is helping patients achieve weight loss previously achievable only with bariatric surgery. But at what cost?

Despite previous excitement around a potential link between GLP-1 drugs and a reduced risk of cancer, new research suggests the popular medications “probably have little or no effect” on a person’s ...

People who quit taking popular GLP-1 drugs such as Ozempic might their jeopardize heart health, according to a new study.

Lower blood sugar and increased fat burning – without negatively affecting appetite or muscle mass. These are some of the most promising effects of a new potential drug treatment for people with type ...

SELECT was a large study focused on obesity and cardiovascular disease in people without type 2 diabetes, but it included kidney outcomes as a secondary end point. The data showed that semaglutide ...

Using a blend of computer modeling, structural and cell-based studies, scientists at The Wertheim UF Scripps Institute have designed a group of potential diabetes drugs that reprogram ...

A large epidemiological study of more than 600,000 veterans with diabetes suggests GLP-1 weight-loss medications may reduce drug- and alcohol-related overdoses and deaths ...

Toby Pillinger has received speaker or consultancy fees from Boehringer Ingelheim, Bristol Myers Squibb, Recordati, Lundbeck, Otsuka, Janssen, CNX Therapeutics, Sunovion, ROVI Biotech, Schwabe Pharma, ...